Analyses of molecular structures and obese-induced dynamics of myokines in dogs and cats.
Project/Area Number |
15K07755
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Veterinary medical science
|
Research Institution | Nippon Veterinary and Life Science University |
Principal Investigator |
Ishioka Katsumi 日本獣医生命科学大学, 獣医学部, 教授 (60409258)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | dog / FGF21 / myokine / マイオカイン / イヌ / 肥満 / 犬 / イリシン |
Outline of Final Research Achievements |
Fibroblast growth factor (FGF) 21 is expressed in many canine organs. The molecular structure is similar to those of other species including human beings, suggesting that canine FGF21 has similar functions also in dogs. We can measure blood FGF21 concentrations in dogs using a human ELISA kit (however, the data will be relative values). The average blood concentration of FGF21 in healthy dogs was 0.21 ng/mL (0.011-1.1 ng/mL). There was no gender or age difference. There was no diurnal or daily variations. Fasting and feeding did not cause any effect on blood FGF21 in dogs. Mild exercise did not change blood FGF21 concentrations in dogs. FGF21 showed slightly but significantly higher values in obese dogs. In dogs with tumor, inflammation and liver diseases showed significantly higher FGF21 values than healthy dogs (much higher in dogs with tumor and liver diseases). FGF21 might be a new blood test item which reflects tumor and liver diseases, and metabolic condition in dogs.
|
Report
(4 results)
Research Products
(3 results)